Hester Biosciences Ltd. Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2018
January 29, 2019 at 11:29 am IST
Share
Hester Biosciences Ltd. reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2018. For the quarter, the company reported total revenue of INR 421.13 million compared to INR 322.96 million a year ago. Profit for period was INR 118.59 million compared to INR 65.01 million a year ago. Income from operations was INR 415.56 million compared to INR 319.25 million a year ago. Basic and diluted earnings per share was INR 13.94 compared to INR 7.64 a year ago.
For the nine months, the company reported total revenue of INR 1,239.74 million compared to INR 993.23 million a year ago. Profit for period was INR 314.75 million compared to INR 215.44 million a year ago. Income from operations was INR 1,223.58 million compared to INR 977.69 million a year ago. Basic and diluted earnings per share was INR 37.00 compared to INR 25.33 a year ago.
Hester Biosciences Limited is an India-based animal healthcare company. The Company is engaged in providing vaccines, health products and diagnostic laboratory services. The Company operates through four segments: Poultry Healthcare, Animal Healthcare, Petcare, and Others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, and PPR Vaccine - Sungri/96. Its Poultry Healthcare products include Gumboro I, Gumboro I +, Inactivated Chick ND, Inactivated Coryza, Inactivated Coryza+, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IB+, Inactivated IB-H52, Inactivated IBD, Inactivated IBD ND, Inactivated IBD ND EDS, Inactivated ND IB, Inactivated Pullet ND, Live B1, Live B1 M48, Live FP, Live H120, Live Las, Live Las Mas, Live M48, Live R2B, Live S-One, MD-Bivalent HVT+SB1, MD-HVT (FD), and Thermostable ND. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet and Hestaliv.